MYC and medulloblastoma: Based on these encouraging results, Jonas et al. tested the efficacy of several GABA agonists delivered to a model of intracranial group 3 medulloblastoma with MYC amplification, and they concluded that the benzodiazepine derivative KRM-II-08 is more potent that other agonists, including QHii066, and can offer a greater pro-apoptotic effect in these tumors [111].